MiniMed Group, Inc. Common Stock
MiniMed Group, Inc. (MMED) is a newly public company specializing in medical technologies for diabetes management, including insulin pumps and continuous glucos
MiniMed Group, Inc. (MMED) is a newly public company specializing in medical technologies for diabetes management, including insulin pumps and continuous glucose monitoring (CGM) systems. Its solutions help patients and healthcare providers monitor and regulate blood glucose. Consumables and CGM comprise over 80% of its revenue, serving individuals with Type 1 and Type 2 diabetes.
Source Core product, explicitly mentioned as impacting gross margin and a major revenue driver. Includes specialized chemicals, electrodes, biocompatible polymers for Simplera, Instinct, and next-gen sensors.
Confidence: high
Source Essential for MiniMed Flex, 780G, and Fit pumps. Includes microcontrollers, communication modules, and other integrated circuits.
Confidence: high
Source Used extensively for device housings (pumps, transmitters), reservoirs, infusion set tubing, and sensor components. Examples include polypropylene, polycarbonate, PEEK, PPSU.
Confidence: high
Source Represent a significant portion of recurring revenue (82% with CGM). Made of plastics and small needles.
Confidence: high
Source Directly impacts manufacturing capacity and yields, which are key to gross margin improvement.
Confidence: high
Source Used for needles in infusion sets, internal pump mechanisms, and potentially electrodes in sensors. Stainless steel, titanium, aluminum are common.
Confidence: medium
Source Essential for powering portable insulin pumps and CGM transmitters. AA batteries are mentioned for the MiniMed 780G.
Confidence: medium
Source Required for sterile medical devices and product distribution.
Confidence: medium
Source Significant investment area for innovation (Flex, Fit, Vivera, next-gen sensor) and a key cost input for product development.
Confidence: high
Source Distributing products globally to U.S. and international markets.
Confidence: medium
Metric/field CGM and RPM claims volume
Cadence quarterly
Why it matters Measures real-world utilization growth for MMED's products under expanded MA coverage, directly impacting revenue potential.
Signal to watch Increasing volume indicates broader market access and utilization, especially for MMED's wearable devices.
Confidence: high
Metric/field GLP-1 prescription volume (e.g., Ozempic, Wegovy, Mounjaro, Zepbound)
Cadence quarterly
Why it matters Monitors the potential substitution risk for CGM and insulin pump demand, especially for Type 2 diabetes management, as GLP-1 adoption grows.
Signal to watch Accelerating growth in GLP-1 prescriptions could signal a headwind for MMED's market.
Confidence: high
Metric/field Total National Health Expenditures (NHE) Annual Growth Rate
Cadence annually (with quarterly updates for some components)
Why it matters Indicates the overall health and growth of the U.S. healthcare market, influencing investment and reimbursement for medical devices.
Signal to watch Sustained or accelerating growth suggests a favorable environment for MedTech companies.
Confidence: medium
Metric/field CPI for Medical Care Services (Series ID: CUSR0000SAM)
Cadence monthly
Why it matters High medical inflation can put pressure on reimbursement rates and increase patient cost burden, potentially affecting adoption of new devices.
Signal to watch Stable or declining growth in medical care CPI is generally favorable for patient affordability and reimbursement stability.
Confidence: medium
Metric/field Real Disposable Personal Income (Series ID: A067RX1)
Cadence monthly
Why it matters Higher disposable income can lead to greater patient willingness and ability to adopt advanced diabetes management technologies with potential out-of-pocket costs.
Signal to watch Sustained growth in real DPI indicates stronger consumer purchasing power and potential for increased adoption of premium medical devices.
Confidence: medium
Metric/field continuous glucose monitor (worldwide, past 90 days)
Cadence daily/weekly (trends)
Why it matters Indicates general public awareness and interest in CGM technology, a core product for MMED, and overall market expansion.
Signal to watch Increasing search interest suggests growing market awareness and potential demand for CGM devices.
Confidence: high
Metric/field Sentiment score/volume of mentions for 'MiniMed', 'Flex', 'Simplera', 'Instinct', 'Vivera'
Cadence daily/weekly
Why it matters Provides real-time patient sentiment, user experience feedback, and early indications of product reception and issues for MMED's devices.
Signal to watch Positive sentiment and increasing discussion volume around new products (Flex, Fit, Vivera) indicate strong adoption and satisfaction.
Confidence: high
Metric/field Number of new approvals/clearances for 'insulin pump', 'continuous glucose monitor', 'automated insulin delivery system'
Cadence continuous/monthly
Why it matters Tracks regulatory progress and market entry for new, clinically validated wearable technologies, including MMED's pipeline and competitors.
Signal to watch Monitoring competitor approvals and MMED's own pipeline progress (e.g., Fit, Vivera, next-gen sensor) provides insight into market dynamics and future product availability.
Confidence: high
Metric/field 'MiniMed Vivera' study status (e.g., 'Completed', 'Results Available')
Cadence event_driven (updates upon status change)
Why it matters Provides transparency on the progress and eventual data release for key MMED pipeline products, directly impacting future revenue streams.
Signal to watch Transition to 'Completed' and then 'Results Available' indicates progress towards regulatory submission and launch, a positive signal for MMED's innovation pipeline.
Confidence: high
Metric/field 'Ozempic', 'Wegovy', 'Mounjaro', 'Zepbound' (combined or individual, worldwide, past 90 days)
Cadence daily/weekly (trends)
Why it matters High and increasing public interest in GLP-1 drugs could indicate a growing shift in diabetes and weight management, posing a long-term risk to device demand.
Signal to watch Sustained increase in search interest for GLP-1s could signal increasing competitive pressure and potential market shifts away from device-based therapies.
Confidence: medium
Metric/field Shipments of 'insulin pumps', 'CGM sensors', 'insulin pump consumables' (by manufacturer, region)
Cadence monthly/quarterly
Why it matters Provides granular, real-world data on demand trends and market share for MMED's core products and competitors, reflecting actual sales performance.
Signal to watch Increasing shipments for MMED's products (Flex, Simplera, Instinct) and overall market growth are positive signals for MMED's commercial execution.
Confidence: high
Metric/field Total employee headcount, number of open job postings (especially in R&D, manufacturing, sales for new products like Flex, Fit, Vivera) for MiniMed Group, Inc.
Cadence monthly
Why it matters Indicates the company's investment in growth areas, capacity expansion, and overall operational health, providing insight into strategic priorities.
Signal to watch Increasing hiring in key product areas (e.g., manufacturing for Fit, R&D for next-gen sensors) suggests confidence in future growth and successful product launches.
Confidence: medium
Metric/field Daily/weekly download ranks, user reviews, and sentiment for 'MiniMed Connect' and 'MiniMed Go' apps in key markets (US, Europe).
Cadence daily/weekly
Why it matters Direct measure of patient engagement with MMED's digital ecosystem and new product adoption (e.g., Flex with app control, MiniMed Go).
Signal to watch Improving app rankings, increasing downloads, and positive user reviews indicate strong product adoption and user satisfaction, crucial for ecosystem growth.
Confidence: medium
Metric/field Supplier lead times, component availability, manufacturing capacity utilization for diabetes medical devices (specifically for MMED and key competitors)
Cadence weekly/monthly
Why it matters Provides insights into potential manufacturing bottlenecks, supply chain resilience, and capacity to meet demand for new product launches like Flex and Fit.
Signal to watch Stable or improving supply chain metrics indicate smooth production and ability to scale, reducing risks to product availability.
Confidence: medium
Metric/field Estimated digital ad spend, ad creatives, and impression volume for 'MiniMed', 'Dexcom', 'Tandem Diabetes' (and their products) across platforms (social, display, search).
Cadence monthly
Why it matters Reveals marketing intensity, competitive strategies, and investment in driving patient awareness and adoption for diabetes devices.
Signal to watch Increased ad spend by MMED for new products (Flex, Fit, Go) indicates strong commercialization efforts; monitoring competitor spend shows market dynamics.
Confidence: medium
MiniMed (MMED) is poised for sustained growth in diabetes management, driven by its accelerated pipeline of innovative wearable insulin delivery systems and con
MiniMed (MMED) is poised for sustained growth in diabetes management, driven by its accelerated pipeline of innovative wearable insulin delivery systems and continuous glucose monitors. The successful launches of Flex and Instinct, coupled with upcoming Fit (patch pump) and the Vivera fully closed-loop algorithm, are expanding market reach into MDI and Type 2 patients. Despite near-term separation costs and GLP-1 substitution risks, strong product adoption and operational execution underpin a compelling long-term investment case as of 2026-09-09.
MiniMed is demonstrating strong commercial momentum with its new product launches, including MiniMed Flex in the U.S. and Instinct internationally. The Flex system is successfully expanding the company's reach into new MDI patients and driving competitive conversions, with U.S. new pump sales increasing over 20% year-over-year.
The company's innovation pipeline is advancing ahead of schedule, with key milestones achieved for MiniMed Fit (patch pump) and the Vivera fully closed-loop algorithm. Fit's 510(k) FDA filing was completed early, and Vivera's U.S. pivotal trial enrollment is complete, positioning MiniMed to launch these differentiated products in 2027 and capture significant market share.
MiniMed is building a comprehensive and differentiated ecosystem for diabetes management, offering various form factors (tubed, patch, smart MDI) and advanced algorithms. The upcoming Vivera algorithm, designed to eliminate meal announcements, and a next-generation extended wear sensor will enhance user experience, simplify therapy, and strengthen MiniMed's competitive advantage in the underpenetrated AID market.
The increasing adoption and expanding indications of GLP-1 medications pose a potential substitution risk for continuous glucose monitoring (CGM) and related diabetes management devices. While MiniMed is expanding its market, a significant shift towards pharmaceutical management of diabetes and obesity could moderate demand for its wearable technologies in the long term.
As a newly independent public company, MiniMed is incurring significant separation and stand-alone build-out costs, which negatively impacted its Q1 FY27 operating and free cash flow. Although management expects cash generation to improve, these transitional expenses could continue to pressure financial performance and flexibility in the near to medium term.
MiniMed operates in a highly competitive diabetes technology market, facing rivals who are also advancing their product pipelines and increasing international efforts. While MiniMed's new products are performing well, maintaining market share and securing timely, favorable reimbursement for innovative but newer wearable categories could be challenging, potentially slowing adoption despite product differentiation.
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| MiniMed Fit FDA 510(k) Approval and U.S. Commercial Launch | Entry into the fastest-growing patch pump segment with MiniMed Fit, offering a differentiated product (300-unit reservoir, 7-day wear, SmartGuard algorithm), will expand MiniMed's addressable market and drive competitive conversions. | Look for the official FDA approval announcement for MiniMed Fit. Confirm the full U.S. launch timeline (expected by summer 2027) and any updates on manufacturing capacity beyond the initial 20,000 patients. | Bullish if FDA approval is received, especially if it occurs earlier than the 'summer next year' expectation, signaling accelerated market entry. | Company press releases, FDA 510(k) database, MiniMed's Q2 FY27 earnings call (expected late fall/early winter 2026) and subsequent earnings calls. | FDA Device Approvals Database (search for 'MiniMed Fit'); Google Trends: 'MiniMed Fit' search volume. | IQVIA DeviceTrack: U.S. patch pump market share trends post-launch; Thinknum: MiniMed job postings for Fit sales/marketing roles. |
| New Pumps Sold (NPS) and CGM Attachment Rate Growth | These metrics are direct indicators of MiniMed's commercial execution, market penetration, and the expansion of its recurring revenue base through CGM and consumables, which represent 82% of total revenue. | Monitor year-over-year and sequential growth rates for NPS and CGM attachment rates in Q2 FY27 and subsequent quarters. Specifically, observe if U.S. NPS growth remains strong (e.g., >20% YoY) and if the CGM attachment rate continues to trend upwards (e.g., >69%). | Bullish if NPS growth and CGM attachment rates continue to accelerate or maintain high levels, especially when excluding any one-time benefits like the extra week in Q1. | Company earnings reports (Q2 FY27 expected late fall/early winter 2026) and investor presentations. | IQVIA DeviceTrack (if publicly available or through news reports): Device prescriptions and shipments for wearable health; Google Trends: 'MiniMed pump' and 'MiniMed CGM' search volume. | IQVIA DeviceTrack: MiniMed pump and CGM unit sales/prescriptions; Bloomberg Supply Chain: Component orders for MiniMed devices as a proxy for production. |
| Next-Generation Extended Wear Sensor Pivotal Trial Start | The commencement of the pivotal trial for the next-generation extended wear sensor demonstrates MiniMed's long-term innovation pipeline, promising improved user experience (longer wear) and future margin expansion through manufacturing efficiencies. | Confirm that the pivotal trial has commenced in October 2026 as planned, and monitor for any subsequent updates on its progress, target wear duration, or feature set. | Bullish if the trial starts on schedule and initial updates indicate a competitive wear duration and strong performance, signaling continued product leadership and future growth drivers. | Company press releases, MiniMed's Q2 FY27 earnings call (expected late fall/early winter 2026), and ClinicalTrials.gov. | Google Trends: 'MiniMed extended wear sensor' search volume; industry news sites covering diabetes technology advancements. | MedTech Insight: Sensor market analysis and competitive landscape reports; Expert calls with diabetes key opinion leaders on future sensor technology trends. |
| MiniMed Flex European Commercial Launch | The European launch of MiniMed Flex expands the reach of MiniMed's newest pump system into significant international markets, driving pump sales and CGM adoption in underpenetrated regions, which is crucial for overall revenue growth. | Monitor for specific country rollout announcements, initial sales figures, and adoption rates in Europe following the expected November 2026 launch. Pay attention to commentary on performance in contested markets. | Bullish if initial sales and adoption rates in key European markets (e.g., Western Europe) are strong and comparable to or exceed the U.S. Flex launch performance, indicating successful international expansion. | Company press releases, MiniMed's Q2 FY27 earnings call (expected late fall/early winter 2026), and industry reports. | Google Trends: 'MiniMed Flex Europe' search volume; diabetes patient forums/subreddits in Europe for user sentiment and early feedback. | IQVIA DeviceTrack: European MiniMed Flex prescriptions/shipments; SimilarWeb: MiniMed Europe website traffic trends. |
| Vivera Fully Closed-Loop Algorithm U.S. Pivotal Trial Data Readout and FDA Submission | Vivera is positioned as a 'category-defining platform' that dramatically reduces user burden and expands AID penetration, particularly for Type 2 patients, reinforcing MiniMed's leadership in automated insulin delivery. | Anticipate the announcement of pivotal trial data results (expected after the 3-month study completion from the September 1, 2026 enrollment completion), followed by the FDA submission. | Bullish if trial data demonstrates strong glycemic outcomes (e.g., Time in Range above ADA guidelines) with minimal user input, validating its 'fully closed-loop' claim and potential for broad adoption. | Company press releases, presentations at major scientific conferences (e.g., ADA Scientific Sessions in June 2027), SEC filings, and MiniMed's Q2 FY27 and subsequent earnings calls. | ClinicalTrials.gov (for study status updates); Reddit communities (e.g., r/diabetes) for patient and clinician reactions to early data presentations. | GlobalData: Diabetes pipeline tracking; KOL (Key Opinion Leader) surveys on Vivera's potential impact and differentiation. |
U.S. revenue acceleration, driven by the MiniMed Flex launch, is vital as it signifies successful penetration in a key market, validates product strategy, and c
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| U.S. Revenue Growth | 13% | U.S. revenue acceleration, driven by the MiniMed Flex launch, is vital as it signifies successful penetration in a key market, validates product strategy, and contributes significantly to overall company growth and investor confidence. |
| New Pumps Sold (NPS) | 7.7% | NPS is a crucial indicator of MiniMed's installed base expansion, directly driving future recurring revenue from continuous glucose monitoring (CGM) and consumables, and demonstrating the success of new pump launches in attracting new patients and competitive conversions. |
| Organic Revenue Growth | 15.8% | This metric reflects the overall top-line performance and market acceptance of MiniMed's new products like Flex and Instinct, indicating the company's ability to capture market share and expand the automated insulin delivery (AID) market. |
Will the European launch of MiniMed Flex in November, alongside continued U.S. ramp-up of Flex and Go, drive significant sequential acceleration in new pump sal
Will the European launch of MiniMed Flex in November, alongside continued U.S. ramp-up of Flex and Go, drive significant sequential acceleration in new pump sales and CGM attachment rates, confirming strong international and MDI market penetration?
Can MiniMed provide positive updates on the Vivera fully closed-loop algorithm's pivotal trial data and FDA submission timeline, and demonstrate continued strong retention and adoption among Type 2 patients, reinforcing its competitive differentiation?
Will MiniMed's underlying gross margin improvements and operational leverage lead to the expected sequential EBITDA margin expansion in Q2 and beyond, and will the company demonstrate a clear path to positive free cash flow, excluding stand-up costs, as TSA exits progress?
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Accelerating commercial growth and new product launches: Management highlighted strong organic growth driven by successful launches like MiniMed Flex with Simplera in the U.S., Instinct with MiniMed 780G internationally, and MiniMed Go. They emphasized Flex's role in expanding reach to new MDI patients and driving competitive conversions. 2. Advancing the innovation pipeline: Que Dallara detailed significant progress on upcoming products, including the early 510(k) filing for MiniMed Fit (patch pump), CE Mark approval for MiniMed Flex in Europe, completion of enrollment for the Vivera fully closed-loop algorithm's U.S. pivotal trial, and IDE approval for a next-generation extended wear sensor. 3. Operational execution as a stand-alone company and margin expansion: Chad Spooner discussed progress on exiting Transition Service Agreements (TSAs) with Medtronic, improving gross margins (especially Simplera yields and warranty expense), and driving operating leverage, reaffirming full-year EBITDA margin guidance. | Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management emphasized strong commercial momentum, driven by successful new product launches, which are expanding their installed base and driving competitive conversions. They highlighted significant progress across their innovation pipeline, with key milestones achieved ahead of schedule for Fit, Vivera, and a next-generation sensor, reinforcing their long-term product leadership. The tone was optimistic, with management consistently 'moving the calendar to the left' on product timelines and expressing confidence in their ability to deliver on commitments, improve financial performance, and capture the significant underpenetrated market opportunity in automated insulin delivery, particularly for Type 2 patients. | Prior Quarter'S Y/Y Growth By SegmentFor Q4 Fiscal Year 2026: Overall organic growth was 8.7%. U.S. net sales grew 1.5%. International net sales grew 12.2% organic. CGM grew mid-teens. Consumables grew mid-single digits. New pump sales declined year-over-year. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Fit launch capacity and Vivera milestones/new patient starts acceleration: Travis Steed asked about the 20,000 patient capacity for Fit at launch and what's left for Vivera approval. Que Dallara responded that they are working on capacity beyond 20,000 and preparing for early approval scenarios, with the Vivera study being 3 months, followed by data analysis and submission. 2. Confidence in margin expansion and details on Q1 accelerated investment: Travis Steed inquired about the $8 million accelerated investment in Q1 and confidence in future margin expansion. Chad Spooner clarified that the $8 million was a timing shift for targeted investments (e.g., Fit FDA submission, Flex sales/marketing) and would not impact full-year EBITDA. He expressed confidence in gross margin improvement due to better-than-expected Simplera yields and improved warranty expense. 3. International pump shipment acceleration post-Instinct and overall share-taking ability: Patrick Wood asked if management was surprised by the incremental pump shipments after the Instinct launch and if this indicates a faster ability to take market share. Que Dallara stated that the market is expanding, with the majority of new Flex customers coming from MDI, and competitive conversions doubling year-over-year, attributing this to new form factors and CGMs. | Revenue SegmentsOverall organic growth was 16% (low double digits excluding the extra week). U.S. revenue grew 13% (high single digits excluding the extra week). International revenue grew 16.9% organic (low double digits excluding the extra week). Pumps grew in the low 20s. CGM grew in the high teens. Consumables grew low double digits. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketMiniMed Flex is expanding reach into new patients, with the majority of sales going to MDI patients new to pump therapy. MiniMed Go, a smart MDI solution, aims to reach over 2.5 million people in the U.S. using multiple daily injections, with more than half of early orders coming from patients new to MiniMed. Type 2 diabetes represents one of the largest opportunities in AID, with approximately 40% of new starts in the U.S. coming from Type 2 patients. The Instinct 15-day sensor allows MiniMed to reach over 4.5 million avid sensor users on intensive insulin therapy. MiniMed Fit, a patch pump, is expected to address a new segment of patients who prefer this form factor, particularly MDI patients. The company believes automated insulin delivery remains greatly underpenetrated globally, and Type 2 diabetes is still in the early stages of AID adoption. | About CompetitionMiniMed Flex is driving competitive conversions from tubed and tubeless competitor systems. The company's new products are performing well in contested international markets. MiniMed believes its Vivera algorithm has advantages competitors cannot quickly replicate, including over a decade of proprietary insulin and CGM data, digital twin technology, and an algorithm architecture designed to mimic a healthy pancreas. Vivera is expected to further expand the gap between MiniMed and the competition. The transcript notes that at least one competitor is increasing efforts in the international arena. | About The Broader IndustryThe automated insulin delivery (AID) market remains significantly underpenetrated globally. Type 2 diabetes is still in the early stages of AID adoption, with millions managing diabetes with injections without smart technology. The patch pump segment is identified as the fastest-growing segment of the insulin pump market. Sensor longevity remains a key purchasing criterion in the market. | Where Things Are HeadedMiniMed is building the 'next generation of MiniMed, one company, every option, one ecosystem.' The U.S. launch of Flex is in its early stages with a strong growth runway ahead. MiniMed Go is envisioned as both a meaningful MDI opportunity and a pathway to AID therapy. Vivera, the fully closed-loop algorithm, is expected to be on the U.S. market in the second half of calendar year 2027 for both MiniMed Flex and MiniMed Fit users. MiniMed Fit, a patch pump, is expected to have a full U.S. launch by summer next year. The next-generation MiniMed extended wear sensor recently received IDE approval, with a pivotal trial expected to begin in October. The company plans to continue investing aggressively in technologies to define the next generation of diabetes management, including sensors, to sustain growth and expand margins beyond the current product cycle. | Updates On ThemeMiniMed | Bullish-Leaning Quotes (Short)Organic growth was 16% and ahead of expectations. U.S. new pumps sold increased by over 20% year-over-year. Flex is doing exactly what we designed it to do. It is expanding our reach into new patients, driving competitive conversions and strengthening our position in AID. MiniMed Flex received CE Mark approval well ahead of our calendar year end target. We completed the 510(k) filing for Fit with FDA ahead of our four targets. We have recently completed enrollment in our U.S. pivotal trial ahead of schedule. MiniMed is the only company with a fully enrolled U.S. pivotal trial for a fully closed-loop algorithm. Vivera has the potential to expand the penetration of automated insulin delivery by dramatically reducing the burden placed on both patients and providers. We are building for the next quarter, the next year and the next decade. | Bearish-Leaning Quotes (Short)Simplera currently carries a lower margin than our legacy and interesting sensors, and that mix impact is reflected in our gross margin this year. Operating cash flow in the quarter was a use of cash of $49 million and capital expenditures were $41 million. As a result, free cash flow was a use of cash of $90 million. Our near-term cash flow profile reflects separation and stand-alone company build-out activities that are not indicative of the ongoing cash generation of the business. We do not have it in our fiscal year '27 because as Que said, we can't predict when the agency will approve. | HiringMiniMed's dedicated primary care sales force was fully deployed near the end of Q1 and is now gaining traction. The company acknowledged the commitment, dedication, and passion of its employees around the world for their work in launching products, advancing clinical programs, expanding manufacturing capacity, and increasing patient access while operating as a newly stand-alone company. |
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| MMED_99ed2845 | November of this year | 2026-11-01 | 2026-11-30 | European commercial launch of MiniMed Flex. | This launch follows CE Mark approval and is expected to drive strong growth in international markets by expanding reach into new patients and increasing competitive conversions. | Ticker | 2026-09-01 | earnings_transcript |
| MMED_f53c1ad9 | October | 2026-10-01 | 2026-10-31 | Start of pivotal trial for MiniMed's next-generation extended wear sensor in the U.S. | This program demonstrates continued innovation beyond current products, aiming to improve user experience, strengthen competitive position, and be accretive to margins through longer wear duration. | Ticker | 2026-09-01 | earnings_transcript |
| MMED_21687391 | by summer next year | 2027-06-01 | 2027-08-31 | Full U.S. launch of MiniMed Fit, a patch pump. | Fit brings MiniMed's differentiated therapy platform to the fastest-growing segment of the insulin pump market, expanding reach into new patients and driving competitive conversions. | Ticker | 2026-09-01 | earnings_transcript |
